Products for Research Use Only
RegisterLogin

Insulin glargine

CAT: 0804-HY-108719-01Size: 100 UDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-108719-01Size:100 U
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Insulin glargine is a long-acting insulin analog. Insulin glargine has the effect of lowering blood sugar and can be used in the research of diabetes. In addition, high doses of Insulin glargine can promote the proliferation of bladder cancer cells[1][2][3][4].
CAS Number
160337-95-1
UNSPSC
12352209
Hazard Statement
H302, H315, H319, H335
Target
Akt; Insulin Receptor
Type
Peptides
Related Pathways
PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/insulin-glargine.html
Purity
95.00
Solubility
10 mM in DMSO
Smiles
O=C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSSC[C@@H](C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CSSC[C@@H](C(NCC(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H]([C@H](O)C)C(N6[C@@H](CCC6)C(N[C@@H](CCCCN)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC7=O)C(NCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC8=O)C(N[C@@H](CSSC[C@@H](C(NCC(N[C@@H](CO)C(N[C@@H](CC9=CNC=N9)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CC%10=CC=C(C=C%10)O)C(N[C@@H](CC(C)C)C(N[C@H]7C(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CC(C)C)NC([C@H](CC%11=CNC=N%11)NC([C@H](CCC(N)=O)NC([C@H](CC(N)=O)NC([C@H](C(C)C)NC([C@H](CC%12=CC=CC=C%12)N)=O)=O)=O)=O)=O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@H]8[C@@H](C)CC)=O)=O)=O)=O)=O)=O)=O)=O)CN
Molecular Formula
C267H404N72O78S6
Molecular Weight
6062.89
Precautions
H302, H315, H319, H335
References & Citations
[1]Hwang HG, et al. Recombinant Glargine Insulin Production Process Using Escherichia coli. J Microbiol Biotechnol. 2016;26 (10) :1781-1789. |[2]Stammberger I, et al. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol. 2002 May-Jun;21 (3) :171-9.|[3]Li Y, et al. Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice. Med Sci Monit. 2018 May 19;24:3293-3300.|[4]Liu S, et al. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. Diabetes Res Clin Pract. 2011 Feb;91 (2) :177-82.
Shipping Conditions
Isolate blue ice and the product with bubble pack to avoid direct contact
Storage Conditions
Store at 4°C, do not freeze
Scientific Category
Peptides
Clinical Information
Launched

Related Products

CatalogName
HY-P4070Insulin icodec
HY-109556-01Insulin Detemir
HY-P1156-01Insulin (cattle)
HY-108743-01Insulin degludec
HY-109530-01Insulin lispro
HY-P4062Insulin peglispro
HY-109555Insulin glulisine
HY-P3479-01Insulin (swine)
HY-108767-01Insulin aspart
HY-P0035-01Insulin (human)

Alternative Products

CatalogName
GTR19036636-01Insulin glargine
GTR17946464-01Insulin Glargine Antibody
347253-01Insulin Glargine discontinued
TRC-I666560-5MGInsulin Glargine (>90%)
HF990016-01Research Grade Insulin Glargine
E55K0786Insulin Glargine ELISA Kit
E47M33122Insulin Glargine Mouse mAb
AR-I01570-01Insulin Glargine Metabolite M2
A10119-100UGInsulin Glargine Monoclonal Antibody
N1381-01Insulin Glargine Antibody (3F12)

Popular Products